It is known that anti-EGFR (epidermal growth factor receptor) ADC, with monomethyl auristatin F (MMAF) as a tubulin polymerization inhibitor, via a non-cleavable maleimidocaproyl (MC) linker, ABT-414 (depatuxizumab mafodotin) [46], and anti-EGFR ADC with DM1 (mertansine) as a tubulin polymerization inhibitor, via a non-cleavable maleimidomethylcyclohexane-1-carboxyl (MCC) linker, AMG-595 [47], exhibited high antitumor activity in preclinical glioblastoma tumor models [48]. The gene discussed is EGFR; the disease is neoplasm.